Century Drugs Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 3.00 M
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.80 M
- Revenue Growth 85.92%
- Profit Growth 30.68%
- Ebitda 26.90%
- Net Worth 13.58%
- Total Assets 46.23%
About Century Drugs
Century Drugs Private Limited (CDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 10 April 2012 and has a history of 12 years and nine months. Its registered office is in Dhar, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹2.80 M.
Kapil Sukhija and Vimalchand Jain serve as directors at the Company.
Company Details
- Location
Dhar, Madhya Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24233MP2012PTC028157
- Company No.
028157
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Apr 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Century Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kapil Sukhija  | Director | 18-Jan-2013 | Current |
| Vimalchand Jain | Director | 10-Apr-2012 | Current |
Financial Performance of Century Drugs.
Century Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 85.92% increase. The company also saw a substantial improvement in profitability, with a 30.68% increase in profit. The company's net worth Soared by an impressive increase of 13.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Century Drugs?
In 2020, Century Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.80 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.28 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Apr 2016 | Others | ₹2.80 M | Open |
How Many Employees Work at Century Drugs?
Century Drugs has a workforce of 8 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Century Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Century Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
